This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.32/34/123

Analysis of long-term response to first-line afatinib in the LUX-Lung 3, 6 and 7 trials in advanced EGFRm+ NSCLC

Martin Schuler, James Chih-Hsin Yang, Lecia V. Sequist, Yi-Long Wu, Caicun Zhou, Sarayut L Geater, Tony Mok, Eng-Huat Tan, Cheng-Ping Hu, Nobuyuki Yamamoto, Jifeng Feng, Kenneth O’Byrne, Shun Lu, Vera Hirsh, Yunchao Huang, Stuart Ellis, Carl Samuelsen, Angela Märten, Jean Fan, Keunchil Park, Luis Paz-Ares

1200.32_34_123 LL367 LTR - WCLC 2017

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Park K, et al. Lancet Oncol 2016;17(5):577–89

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang JC, et al. The Lancet Oncology, Volume 16, Issue 2, February 2015, Pages 141-151

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer overall survival data from the phase Iib LUX-Lung 7 trial

Paz-Ares L, et al. Annals of Oncology 1-9 2017 doi: 10.1093/annonc/mdw611

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Yang, et al. Ann Oncol (2016) 27 (11): 2103-2110. doi: 10.1093/annonc/mdw322

First-line afatinibfor advanced EGFRmutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the LUX-Lung 3, 6 and 7 trialsMartin

Schuler M, et al. ECCO 2017:1 991

Related information

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

WCLC 2017

Find information on afatinib and nintedanib's clinical data and Boehringer Ingelheim's activities at WCLC 2017
Back to top